KR860700263A - 정제 및 삼중 클론된 간염 a비루스 - Google Patents

정제 및 삼중 클론된 간염 a비루스

Info

Publication number
KR860700263A
KR860700263A KR860700275A KR860700275A KR860700263A KR 860700263 A KR860700263 A KR 860700263A KR 860700275 A KR860700275 A KR 860700275A KR 860700275 A KR860700275 A KR 860700275A KR 860700263 A KR860700263 A KR 860700263A
Authority
KR
South Korea
Prior art keywords
virus
hepatitis
supervised
directed
triple
Prior art date
Application number
KR860700275A
Other languages
English (en)
Inventor
리차드 제이. 대머
스테펜엠 헤인스톤.
이안디. 거스트
러버트 에이치. 퍼셀
Original Assignee
미국상무성 다비드 티. 모우리
미합중국
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24615385&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR860700263(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 미국상무성 다비드 티. 모우리, 미합중국 filed Critical 미국상무성 다비드 티. 모우리
Publication of KR860700263A publication Critical patent/KR860700263A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/08—Inactivation or attenuation by serial passage of virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32451—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32461—Methods of inactivation or attenuation
    • C12N2770/32464—Methods of inactivation or attenuation by serial passage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

내용 없음

Description

정제 및 삼중 클론된 간염 A비루스
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 균일한 비루스 조성물로된 간염 A생 감독된 비루스 주사약으로 고등 영장류에게 주입함으로서, 고등 영장류 내에 보호항체 반응을 생산하기 위한 방법.
  2. 청구범위 제1항에 있어서, 균일한 비루스 조성물이 계대 접종 도가 적어도 10-30인 삼중 클론된 물질인 것을 특징으로 하는 방법.
  3. 청구범위 제1항에 있어서, 생 감독된 비루스가 균주 HM-175인 것을 특징으로 하는 방법.
  4. 청구범위 제1항에 있어서, 고등 영장류의 주사약이 변형되지 않는 (야생형) 간염 A비루스에 의해서 야기된 A형 간염에 대한 보호를 주는 왁진 형태로 된 것을 특징으로 하는 방법.
  5. 청구범위 제1항에 있어서, 생 감독된 간염 A비루스가 경피 주입으로 투여되는 것을 특징으로 하는 방법.
  6. 청구범위 제1항에 있어서, 생 감독된 간염 A비루스가 구강으로 투여되는 것을 특징으로 하는 방법.
  7. 감독된 후 왁진으로 사용될 수 있는 삼중 클론된 간염 A비루스, 균주 HM-175,로 구성되는 포유동물을 위한 계량된 왁진.
    ※참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR860700275A 1984-09-19 1985-09-18 정제 및 삼중 클론된 간염 a비루스 KR860700263A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US652067 1984-09-19
US06/652,067 US4620978A (en) 1982-04-07 1984-09-19 Hepatitis A virus purified and triply cloned
PCT/US1985/001769 WO1986001826A1 (en) 1984-09-19 1985-09-18 Hepatitis a virus purified and triply cloned

Publications (1)

Publication Number Publication Date
KR860700263A true KR860700263A (ko) 1986-08-01

Family

ID=24615385

Family Applications (1)

Application Number Title Priority Date Filing Date
KR860700275A KR860700263A (ko) 1984-09-19 1985-09-18 정제 및 삼중 클론된 간염 a비루스

Country Status (16)

Country Link
US (1) US4620978A (ko)
EP (1) EP0196316A4 (ko)
JP (1) JPS62500659A (ko)
KR (1) KR860700263A (ko)
AU (1) AU583306B2 (ko)
CA (1) CA1260392A (ko)
DK (1) DK227786A (ko)
ES (1) ES8701837A1 (ko)
FI (1) FI86376C (ko)
GR (1) GR852293B (ko)
IL (1) IL76417A (ko)
NO (1) NO169601C (ko)
NZ (1) NZ213513A (ko)
PT (1) PT81150B (ko)
WO (1) WO1986001826A1 (ko)
ZA (1) ZA857134B (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894228A (en) * 1982-04-07 1990-01-16 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against hepatitis A virus
USRE37381E1 (en) * 1982-04-07 2001-09-18 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against hepatitis A virus
JPH085804B2 (ja) * 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
US5268292A (en) * 1988-06-27 1993-12-07 Robertson Betty H Reproducible generation of high yields of hepatitis A virus by cell culture
WO1994006446A1 (en) 1992-09-18 1994-03-31 Smithkline Beecham Biologicals, S.A. Hepatitis a virus vaccines
PL178578B1 (pl) * 1993-03-23 2000-05-31 Smithkline Beecham Biolog Zawiesina cząstek 3-0-deacylowanego monofosforylolipidu A i sposób jej wytwarzania oraz kompozycja szczepionki zawierającej antygen w połączeniu z 3-0-deacylowanym monofosforylolipidem A i sposób jej wytwarzania
HRP950097A2 (en) 1994-03-08 1997-06-30 Merck & Co Inc Hepatitis a virus culture process
US5766906A (en) * 1994-07-11 1998-06-16 The University Of North Carolina At Chapel Hill Hepatitis A virus deletion mutants and vaccine formulations containing the same
US10265265B2 (en) * 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164566A (en) * 1978-08-17 1979-08-14 Merck & Co., Inc. Hepatitis a virus cell culture in vitro
US4532215A (en) * 1982-04-07 1985-07-30 The United States Of America As Represented By The Department Of Health And Human Services Isolation of hepatitis A virus strain HM-175

Also Published As

Publication number Publication date
NO169601C (no) 1992-07-15
FI86376B (fi) 1992-05-15
PT81150B (pt) 1987-10-20
IL76417A0 (en) 1986-01-31
FI86376C (fi) 1992-08-25
FI861966A0 (fi) 1986-05-12
NZ213513A (en) 1989-03-29
EP0196316A1 (en) 1986-10-08
CA1260392A (en) 1989-09-26
AU583306B2 (en) 1989-04-27
ES547115A0 (es) 1986-12-01
EP0196316A4 (en) 1987-01-28
ZA857134B (en) 1987-05-27
NO861619A (no) 1986-04-24
DK227786D0 (da) 1986-05-16
FI861966A (fi) 1986-05-12
US4620978A (en) 1986-11-04
WO1986001826A1 (en) 1986-03-27
ES8701837A1 (es) 1986-12-01
GR852293B (ko) 1986-01-21
JPS62500659A (ja) 1987-03-19
AU4862085A (en) 1986-04-08
PT81150A (en) 1985-10-01
IL76417A (en) 1990-12-23
DK227786A (da) 1986-05-16
NO169601B1 (no) 1992-04-06

Similar Documents

Publication Publication Date Title
KR860700263A (ko) 정제 및 삼중 클론된 간염 a비루스
ATE96678T1 (de) Verfahren zur verminderung von hautirritationen bei anwendung von durchdringungsverstaerkenden arzneimittelzusammensetzungen.
FI892824A (fi) Organiskt polymermaterial och jonbytarmembran framstaellt daerav.
KR890016724A (ko) 용융상태에서 광학 이방성을 나타내는 폴리에스테르 수지와 그 조성물
KR890701724A (ko) 아세테이트 저생성 능력을 갖는 미생물 및 그것을 사용한 유용물질의 생성방법
KR910000157A (ko) 흡수성이 개선된 비타민 e 조성물
JPS5662847A (en) Resin composition
JPS55118941A (en) Agricultural film
KR910000901A (ko) 폴리에틸렌 조성물
KR870004079A (ko) 부가중합성 그룹을 함유한 물질의 부피 감소 방법
KR830004443A (ko) 고강도 금속 물품의 제작
KR900006351A (ko) 탄소-규소 결합된 방향족 유기기들을 갖는 유기 폴리실록산류의 산 평형 방법
JPS5333916A (en) Austenitic stainless steel with excellent intra- and intergranular stress corrosion cracking resistance
KR910002428A (ko) 트로치 조성물
EP0342565A3 (de) Verwendung des Thiazol-Derivates Tiprotimod zur Herstellung eines Mittels zur Therapie von Virusinfektionen
Bogler et al. Mönchisches Leben und liturgischer Dienst (Book Review)
JPS52136289A (en) Resin compositions
KR910007943A (ko) N-디클로로포스포릴트리클로로포스파젠 및 그의 중축합 생성물의 불순물의 해로운 영향 보완 방법.
UST982003I4 (en) Stabilized copolyetheresters
WADA et al. Variation in the immunizability of mice against tetanus toxoid
JPS5354288A (en) Improved unsaturated polyester resin composition containing inorganic substa nces
USD238304S (en) Binocular
KR930013153A (ko) 스테인레스강 정련로 슬래그의 분화방지방법
Garden Erratum for “Commentary on Plastic Design in Steel: Deflections Progress Report No. 7 of the Joint WRC-ASCE Committee on Plasticity Related to Design”
FR1274660A (fr) Procédé de préparation de bitumes de pétrole, convenant à la fabrication de combustibles agglomérés, et produits en résultant

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

J2X2 Appeal (before the supreme court)

Free format text: APPEAL BEFORE THE SUPREME COURT FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL